840.34USD+0.69%Mkt Cap: —P/E: 11.911d ago
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammator…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value76.34B $
Revenue (TTM)15.53B $
Gross Profit6.91B $
Net Income (TTM)4.33B $
Revenue/Share150.31 USD
Last Price840.34 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15.4K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS75886F1075
Valuation
P/E (Trailing)11.91
P/E (Forward)—
PEG—
EV/EBITDA16.23
EV/Revenue4.91
P/S—
P/B2.59
EPS (TTM)70.31
EPS (Forward)—
52W Range
799.8070% of range857.53
52W High857.53 USD
52W Low799.80 USD
Profitability
Gross Margin44.46%
Oper. Margin33.11%
EBITDA Margin30.27%
Profit Margin27.87%
ROE14.04%
ROA6.53%
Growth
Revenue Growth16.70%
Earnings Growth-4.50%
Cash Flow & Leverage
Operating CF4.68B $
CapEx (TTM)—
FCF Margin19.73%
FCF Yield—
Net Debt-5.29B $
Net Debt/EBITDA-1.12
Balance Sheet
Debt/Equity8.54
Current Ratio3.33
Quick Ratio2.63
Book Value/Sh316.11 USD
Cash/Share80.06 USD
Dividends
Fwd Div Rate—
Trail. Div Rate3.640 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.108.03M
Float95.78M
Insiders2.08%
Institutions93.45%
Technical
SMA 50947.92 (-11.3%)
SMA 200834.06 (+0.8%)
Beta0.19
S&P 52W Chg20.80%
Avg Vol (30d)217
Avg Vol (10d)336
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—